These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12271007)

  • 1. Effects of atorvastatin on renal function in patients with chronic renal failure.
    Cianciaruso B; Torraca S; Somma G; Pisani A; Sabbatini M
    Nephrol Dial Transplant; 2002 Oct; 17(10):1858-9. PubMed ID: 12271007
    [No Abstract]   [Full Text] [Related]  

  • 2. Atorvastatin attenuates oxidative stress in patients with chronic kidney disease.
    Renke M; Knap N; Tylicki L; Rutkowski P; Neuwelt A; Larczynski W; Wozniak M; Rutkowski B
    Med Sci Monit; 2010 Mar; 16(3):LE3-3. PubMed ID: 20190691
    [No Abstract]   [Full Text] [Related]  

  • 3. HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD)--a pilot study.
    Mackie FE; Rosenberg AR; Harmer JA; Kainer G; Celermajer DS
    Acta Paediatr; 2010 Mar; 99(3):457-9. PubMed ID: 20050832
    [No Abstract]   [Full Text] [Related]  

  • 4. A meta-analysis of randomized trials for effects of atorvastatin on renal function in chronic kidney disease.
    Takagi H; Umemoto T
    Int J Cardiol; 2011 Oct; 152(2):242-4. PubMed ID: 21764159
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial.
    Fassett RG; Robertson IK; Ball MJ; Geraghty DP; Coombes JS
    Atherosclerosis; 2010 Nov; 213(1):218-24. PubMed ID: 20810109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin has no beneficial effect on cardiovascular outcomes in patients with advanced chronic kidney disease.
    Kiberd BA
    Nat Clin Pract Nephrol; 2006 Jul; 2(7):354-5. PubMed ID: 16932460
    [No Abstract]   [Full Text] [Related]  

  • 8. Atorvastatin protects renal function in the rat with acute unilateral ureteral obstruction.
    Kamdar C; Chou SY; Mooppan UM; Kim H; Gulmi FA
    Urology; 2010 Apr; 75(4):853-7. PubMed ID: 20371061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin ameliorates tubulointerstitial fibrosis and protects renal function in chronic partial ureteral obstruction cases.
    Fitzgerald JP; Chou SY; Franco I; Mooppan UM; Kim H; Saini R; Gulmi FA
    J Urol; 2009 Oct; 182(4 Suppl):1860-8. PubMed ID: 19692013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HMG-CoA reductase inhibitors and renal function.
    Campese VM; Park J
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1100-3. PubMed ID: 17942762
    [No Abstract]   [Full Text] [Related]  

  • 11. Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis.
    Robinson JG
    N Engl J Med; 2005 Oct; 353(17):1858-60; author reply 1858-60. PubMed ID: 16252415
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of 4 weeks of atorvastatin administration on the antiinflammatory cytokine interleukin-10 in patients with unstable angina.
    Li JJ; Fang CH
    Clin Chem; 2005 Sep; 51(9):1735-8. PubMed ID: 16120956
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial.
    Fassett RG; Robertson IK; Ball MJ; Geraghty DP; Sharman JE; Coombes JS
    J Atheroscler Thromb; 2010 Mar; 17(3):235-41. PubMed ID: 20032570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Charting new territory by simulated modeling of a clinical trial.
    Tuttle KR
    Clin J Am Soc Nephrol; 2010 May; 5(5):750-2. PubMed ID: 20360306
    [No Abstract]   [Full Text] [Related]  

  • 15. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive Lipitor therapy reduced heart attack and stroke by one-third in patients with chronic kidney disease.
    Cardiovasc J S Afr; 2007; 18(1):62. PubMed ID: 17393007
    [No Abstract]   [Full Text] [Related]  

  • 17. [Do statins have benefit on migraine].
    Otero Uribe JL; López Serrano R
    Med Clin (Barc); 2006 Sep; 127(8):319. PubMed ID: 16949026
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
    Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
    Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins and autonomic function in chronic heart failure.
    van der Harst P; Voors AA; van Gilst WH; van Veldhuisen DJ
    Cardiovasc Drugs Ther; 2005 May; 19(3):167-8. PubMed ID: 16142591
    [No Abstract]   [Full Text] [Related]  

  • 20. Strategies for statins: The CASE for fire and forget.
    Lewis LS
    BMJ; 2008 Feb; 336(7641):406. PubMed ID: 18292146
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.